MorphoSys AG increased spending on research and development by 88% in the third quarter and by 60% in the first nine months of 2021 as it continued to invest in new products and absorb programmes from Constellation Pharmaceuticals Inc, a developer of drugs in the field of epigenetics which it acquired in July. Constellation has two clinical-stage cancer programmes and several products in preclinical development.
